HDT Bio

HDT Bio is a Seattle-based clinical-stage biopharmaceutical company specializing in advanced RNA vaccine technologies. Their focus is on harnessing the immune system to treat and prevent infectious diseases and cancer. They have developed the AMPLIFY™ vaccine platform, which combines self-amplifying RNA (repRNA) with their patented LION™ nanoparticle-based formulation technology. This platform offers several advantages over traditional RNA vaccines, including increased potency, simplified manufacturing, improved temperature stability, and a superior safety profile. HDT Bio is committed to translating their innovations into life-saving vaccines for patients worldwide.

HDT Bio has a diverse portfolio of ongoing research and development projects, including vaccines for COVID-19, shingles, HIV, tuberculosis, Crimean-Congo hemorrhagic fever virus, and Nipah virus. They are also actively developing RNA cancer vaccines that target antigens associated with pancreatic, colon, prostate, breast, and other cancers. Their commitment to global health equity is evident in their partnerships with organizations in Africa, India, South America, and the EU, ensuring that their products are accessible to patients who need them most.

HDT Bio is a Seattle-based, clinical-stage biopharmaceutical development company committed to harnessing the power of the immune system to combat challenging diseases. The company focuses on developing advanced RNA vaccine products that treat and prevent infectious diseases and cancer, utilizing its proprietary LION™ technology to deliver self-amplifying RNA (repRNA) to the immune system. Through its innovative AMPLIFY™ platform, HDT Bio aims to redefine the global vaccine landscape with products that offer superior safety, potency, durability, and simplified manufacturing processes, making advanced treatments accessible to patients worldwide.

HDT Bio cultivates a collaborative and results-oriented culture that values diversity and inclusion. They emphasize a multidisciplinary team approach, bringing together experts from various backgrounds to tackle complex challenges in infectious disease and oncology. The company fosters a commitment to clinical development excellence, driving innovation and ensuring the development of safe and effective solutions. They prioritize global health equity, striving to make their products widely available to improve lives around the world.

HDT Bio prioritizes diversity and inclusion, recognizing that a varied workforce fosters innovation and ensures solutions meet the needs of diverse patient populations. They are committed to building an inclusive culture where everyone feels valued and respected, tapping into a range of perspectives, experiences, and talents to drive success. This dedication is evident in their commitment to global health equity through international partnerships that accelerate access to life-changing solutions for patients worldwide.